Post by Allyfe

Mid-size pharma and biotech sponsors, a question: When your e-TMF vendor says "AI-powered," do you know what that actually means? For most legacy platforms, it means: → AI added on top of systems built in 2010→ Basic keyword search dressed up as "intelligence" → Zero ability to auto-classification, metadata generation, detect anomalies before an inspector does. Here's what AI-native actually looks like: Document classification in seconds, not hours. Upload a document. Our AI reads it, classifies it to DIA reference model, and files it—automatically. No drag-and-drop. No "CTIS_mess_Nov2025" folders. Anomaly detection (coming soon). We're building the system that flags data, records inconsistencies before your monitor catches them. Missing signatures. Mismatched dates. Protocol deviations hiding in plain sight. This is a combination of a semantic and procedural layer. This isn't a feature. It's architecture. Competitors would need to rebuild from scratch to match it. And one more thing: We're EU AI Act compliant by design. While US vendors figure out what "high-risk AI system" means for their retrofit plans, we're already there. If you're running EU trials and tired of making it work with spreadsheets and screenshots, let's talk. The future of sponsor-owned, inspection-ready TMFs isn't coming. It's here. 🔥 in the comments if this resonates. #ClinicalTrials #eTMF #RegulatoryAffairs #Biotech